Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

A new highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...

So I think this is one unmet need. Second, I think when we talk about CAR T, a lot of times we need to think what are the deal breakers for CAR T? So when a patient comes to my clinic, the first two ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...